Condition: Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer · Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
This description comes directly from the study's public registry record.
ZHOU, PhD · 13708384529 · qizhou9128@163.com
Always discuss trial participation with your own doctor first.
| Chongqing Cancer Hospital | Chongqing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06522828